Parkinson's Disease Therapeutics Pipeline Program

The Parkinson's Disease Therapeutics Pipeline Program sits under the Michael J. Fox Foundation for Parkinson's Research and funds pre-clinical and clinical development for disease-modifying or symptomatic Parkinson's interventions. It also covers biomarker tools that inform therapeutic decisions, so the grant is aimed at development-stage teams rather than early discovery. Awards run from $250,000 to more than $5 million, with pre-clinical projects typically spanning one to two years and clinical projects two to three years. Pre-proposals are rolling, then five annual full-proposal cycles run from October 2025 through January 2027, with award announcements within three months of each cycle close. Industry organizations, academic-industry partnerships, and some academic-led projects are eligible, and the route is open internationally. The strongest fit is a team with a defined therapeutic candidate and enough evidence to justify advancement. MJFF excludes early-stage target discovery, tool compound validation, standalone biomarker discovery, simple reformulation, dietary supplements, and natural history studies. Applicants are expected to work from the foundation's RFA and templates and to meet the program's open-science expectations.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.